Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab Open-Label Extension in Chronic Rhinosinusitis With Nasal Polyps
NCT03478930Phase 3Completed
- Sponsor
- Roche
- Start
- May 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, open-label trial of omalizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (4 cohorts), sponsored by Roche. Primary endpoints: Nasal Polyp Score at 76 weeks, Nasal Congestion Score at 76 weeks and 2 more. Started May 2018; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT03478930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478930.